Prior authorization is moving in two opposite directions inside Medicare at the same time, and spine, orthopedic, and pain practices sit at the exact point where the two collide. On July 21, the House Committee on Energy and Commerce voted 45 to 0 to advance the Improving Seniors' Timely Access to Care Act. The bill would force Medicare Advantage plans to answer standard prior authorization requests within seven days and urgent ones within seventy-two hours, push the process toward a real-time electronic system, and require plans to publicly report their denial data.
That is meaningful relief. It also comes with two catches. The bill covers Medicare Advantage only, and the version advanced by the House Ways and Means Committee on July 15 set the effective date at January 1, 2029. So the help is real, but it is narrow, and it is years away.
Meanwhile, traditional Medicare is going the other way. Through a model called WISeR, the Wasteful and Inappropriate Service Reduction model, CMS has brought technology-driven prior authorization into fee-for-service Medicare for the first time at scale. It launched January 1, 2026 in six states and runs through 2031. And the list of services it screens reads like a spine and pain schedule.
Key Takeaways
The House Energy and Commerce Committee advanced the Improving Seniors' Timely Access to Care Act 45 to 0 on July 21, setting seven-day standard and seventy-two-hour urgent decision windows for Medicare Advantage.
That bill applies to Medicare Advantage only. The Ways and Means version set an effective date of January 1, 2029, so relief is not immediate.
Traditional Medicare is tightening at the same time. The WISeR model added prior authorization for select services in six states starting January 1, 2026, running through 2031.
WISeR targets many spine, orthopedic, and pain procedures, including epidural steroid injections, cervical fusion, and electrical nerve stimulator implants.
Roughly 908,000 of the 1.1 million traditional Medicare patients who used a WISeR service in 2024 received an orthopedic or pain service, so patient impact concentrates in these specialties even though spending is dominated by skin substitutes.
Vendors running WISeR reviews earn a share of the savings from denials, a structure that has drawn scrutiny. CMS has said high-approval providers may earn a gold-carding exemption.
What Did Congress Actually Pass on July 21?
The House Committee on Energy and Commerce approved the Improving Seniors' Timely Access to Care Act by a vote of 45 to 0, clearing it for the full House. The bill would require Medicare Advantage plans to respond to standard prior authorization requests within seven days and urgent requests within seventy-two hours. It would move the process toward a real-time electronic system and require plans to publicly report denial data. The legislation cleared the House Ways and Means Committee 42 to 0 on July 15, and it carries close to 300 House cosponsors. Support is broad, and the neurosurgery societies were among its most vocal backers, framing delayed authorizations as a direct clinical risk for patients with time-sensitive conditions.
Why Is the Relief Narrower Than the Headline Suggests?
Two limits matter for planning. First, scope. The bill touches Medicare Advantage only. It does nothing for traditional Medicare, commercial plans, or Medicaid. Second, timing. The Ways and Means substitute amendment delayed the effective date by a year, to January 1, 2029. A committee vote is also not a law. The bill still needs a full House floor vote, Senate passage, and a signature. For a practice trying to forecast cash flow this year, none of that changes the day-to-day work of getting an authorization approved in 2026.
What Is the WISeR Model, and Why Does It Hit These Specialties?
WISeR brings prior authorization into fee-for-service Medicare, which historically operated almost without it. The model launched January 1, 2026 in Arizona, New Jersey, Ohio, Oklahoma, Texas, and Washington, and it runs through 2031. Technology vendors, including AI-based tools, screen requests, and CMS has said a human clinician must provide a second opinion before any denial based on those tools. The financial design is the part drawing the most attention. Vendors receive a share of the savings tied to the care they deny, which critics argue creates a built-in incentive to say no. The services under review include skin substitutes, epidural steroid injections, cervical fusion, electrical nerve stimulator implants, and knee procedures for osteoarthritis, among others. CMS delayed two services to a later performance year, deep brain stimulation and percutaneous image-guided lumbar decompression for spinal stenosis.
How Many Patients Are Actually Affected, and Where?
Here is the nuance that gets lost in the headlines. According to KFF, WISeR services accounted for 5.3 percent of all Part B spending in traditional Medicare in 2024, up from 1.1 percent in 2019. But most of that spending, about 83 percent, came from skin substitutes, a wound-care product category whose prices spiked. The patient picture looks different. Of the roughly 1.1 million traditional Medicare beneficiaries nationwide who received at least one WISeR service in 2024, about 908,000, or 86 percent, received an orthopedic or pain management service. Only about 98,000 received skin substitutes. So the dollars concentrate in wound care, but the patients concentrate in spine, orthopedic, and pain care. For now the requirement is limited to the six model states, where roughly 207,500 WISeR service users lived in 2024.
Why Should Executives Connect These Two Policies?
Strip away the program names and both changes turn on one question. Who gets to say no, and how are they paid to do it? Congress is trying to limit denials in Medicare Advantage. CMS is expanding a version of the same tool, algorithm-screened prior authorization, into traditional Medicare and pointing it at spine, orthopedic, and pain procedures. The two are not separate stories. They are the same fight over utilization control, arriving from opposite directions, and landing on the same income statement. A practice that treats them as one connected trend will plan better than a practice reacting to each headline in isolation.
What This Means for Your Practice
The immediate exposure is administrative, and it is concrete. If your practice performs epidural steroid injections, cervical fusions, nerve stimulator implants, or similar procedures for traditional Medicare patients in Arizona, New Jersey, Ohio, Oklahoma, Texas, or Washington, those cases now carry a prior authorization step that did not exist a year ago. That means more documentation, more staff time, and more risk of delayed or denied payment if the paperwork is thin.
Three moves make sense now. Know which of your Medicare patients fall under WISeR versus Medicare Advantage, because the rules, timelines, and appeal paths differ. Tighten clinical documentation up front, since the model rewards clean, complete submissions and CMS has signaled that consistently high approval rates can earn a gold-carding exemption. And track your denial and approval rates by payer and procedure, so you can see friction building before it shows up as a cash-flow problem. This is exactly the kind of front-end discipline a revenue cycle partner is built to carry, so your clinicians can stay focused on patients rather than payer portals.
Frequently Asked Questions
Does the July 21 bill help my traditional Medicare patients?
No. The Improving Seniors' Timely Access to Care Act applies to Medicare Advantage plans only. Traditional Medicare, including the WISeR model, is not covered by it.
When would the Medicare Advantage changes take effect?
The version advanced by the House Ways and Means Committee set an effective date of January 1, 2029. The bill also still needs a full House vote, Senate passage, and a presidential signature before it becomes law.
Which of my procedures fall under WISeR?
WISeR screens select services such as epidural steroid injections, cervical fusion, electrical nerve stimulator implants, and knee procedures for osteoarthritis, among others. Deep brain stimulation and percutaneous image-guided lumbar decompression were delayed to a later performance year. Confirm the current CPT list in the CMS WISeR operational guide, since it can change.
Does WISeR apply everywhere?
Not yet. For now it applies in six states: Arizona, New Jersey, Ohio, Oklahoma, Texas, and Washington. CMS has said it may expand the model to more services and states in future years.
What is gold carding, and can we qualify?
Gold carding is an exemption from repeat prior authorization for providers with consistently high approval rates. CMS has indicated it intends to offer this under WISeR. The practical path is a strong, well-documented approval track record, which is easier to build with disciplined front-end processes.
Talk to Cosentus
Prior authorization is getting more complex, not less, and the rules now differ by program, procedure, and state. Cosentus helps specialty practices tighten documentation, track denials, and protect revenue as these policies shift. Start a conversation at cosentus.com/contact or call (800) 378-0049.